New Three-Minute Brain Test Could Revolutionize Alzheimer’s Early Detection

A three-minute brain test utilizing miniature electroencephalogram technology could fundamentally transform how clinicians detect early-stage Alzheimer’s disease, according to researchers at the University of Bath. Described in research published in Brain Communications in September 2025, the Fastball test measures automatic brain responses to rapidly flashing images without requiring conscious memorization or active patient effort, offering a potential screening tool for general practice clinics and home use long before traditional symptoms emerge.

How the Fastball Brain Test Works

Traditional neuropsychological evaluations often rely heavily on a patient’s education level, language skills, or immediate concentration, frequently arriving too late in the disease progression. By contrast, the Fastball method records passive electrical signals emitted by the brain when it encounters images viewed just seconds earlier, according to reporting from Science-et-Vie.

Patients sit quietly while a sequence of images flashes rapidly on a screen for a duration of three minutes. This implicit recognition generates a distinct electrical signature captured by miniature EEG electrodes. According to the study findings, a reduction or disappearance of this specific brain response indicates underlying memory impairment well before clinical symptoms disrupt daily life.

Targeting Mild Cognitive Impairment

The research team tested the technology on 107 volunteer participants, which included 53 individuals diagnosed with mild cognitive impairment. The results demonstrated a clear distinction between healthy control subjects and those with amnesic mild cognitive impairment, a condition known to carry a higher risk of progressing toward dementia.

Dr. George Stothart, a neuroscientist in the department of psychology at the University of Bath and principal author of the work, emphasized the limitations of standard diagnostics. Current diagnostic tools fail to capture the initial 10 to 20 years of Alzheimer’s disease pathology, noted Dr. Stothart, adding that Fastball provides an objective and rapid way to detect memory decline much earlier.

Fastball offers a solution : détecter le déclin de la mémoire beaucoup plus tôt et de manière plus objective, grâce à un test rapide et passif.

Dr. George Stothart, University of Bath

Implications for Modern Therapeutics

Early detection has grown increasingly critical alongside the development of targeted antibody treatments like donanemab and lecanemab. Clinical data indicates these therapeutic agents deliver maximum efficacy when administered during the earliest stages of Alzheimer’s disease, prior to extensive neuronal destruction.

Standard structural screening methods, such as brain scans, lumbar punctures for cerebrospinal fluid, and blood biomarkers, reveal physical pathology but remain expensive and less accessible for widespread population screening. The research group points out that Fastball offers a portable, inexpensive alternative capable of functioning in real-world clinical environments.

Il existe un besoin urgent d’outils précis et pratiques pour diagnostiquer la maladie d’Alzheimer à grande échelle,

Study Authors, Brain Communications

The next phase of evaluation involves testing the Fastball technology directly inside general practitioner offices to validate its performance under everyday clinical conditions.